Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Cited by (1,002)

Items 501–600 of 1,002

1. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data
   Iain C. Macdougall, Claire White, Stefan D. Anker, Sunil Bhandari, Ken Farrington, Philip A. Kalra, John J.V. McMurray, Heather M. Murray, Retha D. Steenkamp, Charles Tomson et al. · 2018 · American Journal of Nephrology
2. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin
   Takeshi Hasegawa, Jennifer L. Bragg‐Gresham, Ronald L. Pisoni, Bruce M. Robinson, Shunichi Fukuhara, Takashi Akiba, Akira Saitō, Kiyoshi Kurokawa, Tadao Akizawa · 2010 · Kidney International
3. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?
   Amy Barton Pai, Garba · 2012 · Journal of Blood Medicine
4. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes
   Yi Zhang, Mae Thamer, James S. Kaufman, Dennis J. Cotter, Miguel Ángel Hernán · 2011 · Kidney International
5. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
   Szu‐Chun Hung, Yao‐Ping Lin, Der‐Cherng Tarng · 2013 · Journal of the Formosan Medical Association
6. The Labile Side of Iron Supplementation in CKD
   Itzchak N. Slotki, Zvi Ioav Cabantchik · 2015 · Journal of the American Society of Nephrology
7. The Role of Correction of Anaemia in Patients with Congestive Heart Failure: A Short Review
   Donald S. Silverberg, Dov Wexlerb, Adrian Iaina, Doron Schwartz · 2008 · European Journal of Heart Failure
8. Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality
   Pranav Sandilya Garimella, Ronit Katz, Kushang V. Patel, Stephen B. Kritchevsky, Chirag R. Parikh, Joachim H. Ix, Linda F. Fried, Anne B. Newman, Michael G. Shlipak, Tamara B. Harris et al. · 2016 · Circulation Heart Failure
9. Preoperative Anemia in Cardiac Operation: Does Hemoglobin Tell the Whole Story?
   Lu Dai, Stephanie L. Mick, Keith R. McCrae, Penny L. Houghtaling, Joseph F. Sabik, Eugene H. Blackstone, Colleen Gorman Koch · 2017 · The Annals of Thoracic Surgery
10. On Stopping a Randomized Clinical Trial for Futility
    Jay Herson, Marc E Buyse, Janet Turk Wittes · 2011 · Springer eBooks
11. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials
    Roberto Minutolo, Maria Elena Liberti, Vittorio Simeon, Ferdinando Carlo Sasso, Silvio Borrelli, Luca De Nicola, Carlo Garofalo · 2023 · Clinical Kidney Journal
12. The Psychological Impact of Hemodialysis on Patients with Chronic Renal Failure
    Liang‐Jen Wang, Cong Che · 2012 · InTech eBooks
13. Effect of Hemoglobin Target on Progression of Kidney Disease: A Secondary Analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) Trial
    Jula K. Inrig, Huiman Xie Barnhart, Donal N. Reddan, Uptal D. Patel, Shelly K Sapp, Robert M. Califf, Ajay K. Singh, Lynda Anne M. Szczech · 2012 · American Journal of Kidney Diseases
14. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose
    Amy Barton Pai, Todd A. Conner, Charles R. McQuade, Jonathan Olp, Paul Hicks · 2011 · BioMetals
15. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury
    Ali C.M. Johnson, Kirsten Becker, Richard A. Zager · 2010 · American Journal of Physiology-Renal Physiology
16. Mortality Associated with Dose Response of Erythropoiesis-Stimulating Agents in Hemodialysis versus Peritoneal Dialysis Patients
    Uyen Duong, Kamyar Kalantar‐Zadeh, Miklos Zsolt Molnar, Joshua J. Zaritsky, Isaac Teitelbaum, Csaba Pal Kovesdy, Rajnish Mehrotra · 2012 · American Journal of Nephrology
17. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?
    Takeshi Nakanishi, Takahiro Kuragano, Shoji Kaibe, Yasuyuki Nagasawa, Yukiko Hasuike · 2012 · Clinical and Experimental Nephrology
18. The Cardiorenal Syndrome: A Review
    Benoy Nalin Shah, Kim Greaves · 2010 · International Journal of Nephrology
19. Association of Hemoglobin and Survival in Peritoneal Dialysis Patients
    Miklos Zsolt Molnar, Rajnish Mehrotra, Uyen Duong, Csaba Pal Kovesdy, Kamyar Kalantar‐Zadeh · 2011 · Clinical Journal of the American Society of Nephrology
20. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States
    Daniel G. Wright, Elizabeth C. Wright, Andrew S. Narva, Constance Tom Noguchi, Paul W. Eggers · 2015 · Clinical Journal of the American Society of Nephrology
21. Dialysis-Induced Myocardial Stunning: The Other Side of the Cardiorenal Syndrome
    Tobias Breidthardt, Christopher William McIntyre · 2011 · Reviews in Cardiovascular Medicine
22. Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort
    Ruth F. Dubin, Rajat Deo, Nisha Bansal, Amanda Hyre Anderson, Peter H Yang, Alan S. Go, Martin Gerard Keane, Ray R. Townsend, Anna C. Porter, Matthew Jay Budoff et al. · 2016 · Clinical Journal of the American Society of Nephrology
23. Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
    Andrew A. House, Mikko Haapio, Johan P.E. Lassus, Rinaldo Bellomo, Claudio Ronco · 2010 · American Journal of Kidney Diseases
24. The relationship between laboratory‐based outcome measures and mortality in end‐stage renal disease: A systematic review
    Amar A. Desai, Allen R. Nissenson, Glenn Matthew Chertow, Mary FARID, Inder SINGH, Martijn G.H. van Oijen, Eric Esrailian, Matthew D. Solomon, Brennan Mason Ross Spiegel · 2009 · Hemodialysis International
25. Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease
    Natalie Ann Bello, Eldrin Foster Lewis, Akshay Suvas Desai, Inder S. Anand, Henry Krum, John J.V. McMurray, Kurt A. Olson, Scott David Solomon, Karl B Swedberg, Dirk Jan van Veldhuisen et al. · 2015 · European Journal of Heart Failure
26. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
    Matti Aapro, Pere Gascón, Kashyap B Patel, George M. Rodgers, Selwyn Fung, Luiz H. Arantes, Jay B. Wish · 2019 · Frontiers in Pharmacology
27. Searching for molecular hypoxia sensors among oxygen-dependent enzymes
    Li Li, Susan Q. Shen, Philip E. Bickler, Matthew P. Jacobson, Lani F. Wu, Steven J. Altschuler · 2023 · eLife
28. Novel drugs and intervention strategies for the treatment of chronic kidney disease
    Hiddo J.L. Heerspink, Dick de Zeeuw · 2013 · British Journal of Clinical Pharmacology
29. Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry
    Takayuki Hamano, Naohiko Fujii, Terumasa Hayashi, Hiroyasu Yamamoto, Kunitoshi Iseki, Yoshiharu Tsubakihara · 2015 · Kidney International Supplements
30. RNA Interference-Mediated Inhibition of Erythropoietin Receptor Expression Suppresses Tumor Growth and Invasiveness in A2780 Human Ovarian Carcinoma Cells
    György Paragh, Suresh Kumar, Zsuzsa Rákosy, Soek-Choel Choi, Xiaowei Xu, Géza Ács · 2009 · American Journal Of Pathology
31. Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease
    Yuji Sato, Shouichi Fujimoto, Tsuneo Konta, Kunitoshi Iseki, Toshiki Moriyama, Kunihiro Yamagata, Kazuhiko Tsuruya, Ichiei Narita, Masahide Kondo, Masato Kasahara et al. · 2017 · Clinical and Experimental Nephrology
32. Erythropoiesis and chronic kidney disease–related anemia: From physiology to new therapeutic advancements
    Valeria Cernaro, Giuseppe Coppolino, Luca Visconti, Laura Rivoli, Antonio Lacquaniti, Domenico Santoro, Antoine Buemi, Saverio Loddo, Michele Buemi · 2018 · Medicinal Research Reviews
33. Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study
    Chronic Kidney Disease Japan Cohort Study Group, Tadao Akizawa, Hirofumi Makino, Seiichi Matsuo, Tsuyoshi Watanabe, Enyu Imai, Kosaku Nitta, Yasuo Ohashi, Akira Hishida · 2011 · Clinical and Experimental Nephrology
34. Anemia in the Preterm Infant: Erythropoietin Versus Erythrocyte Transfusion—It's not that Simple
    Isabelle Von Kohorn, Richard A. Ehrenkranz · 2009 · Clinics in Perinatology
35. Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization
    Karen S. Servilla, Ajay K. Singh, William C. Hunt, Antonia Harford, Dana C. Miskulin, Klemens B. Meyer, Edward John Bedrick, Mark R. Rohrscheib, Antonios Helias Tzamaloukas, Howard Johnson et al. · 2009 · American Journal of Kidney Diseases
36. Medicare and Erythropoietin
    Robert Steinbrook · 2007 · New England Journal of Medicine
37. The new FDA label for erythropoietin treatment: How does it affect hemoglobin target?
    Steven N. Fishbane, Allen R. Nissenson · 2007 · Kidney International
38. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
    V. Prasad · 2007 · Yearbook of Medicine
39. Erythropoietin as a Novel Brain and Kidney Protective Agent
    Elizabeth Moore, Rinaldo Bellomo, Alistair D. Nichol · 2011 · Anaesthesia and Intensive Care
40. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis
    Nicole Rainville, Edward Jachimowicz, Don M. Wojchowski · 2015 · Expert Opinion on Therapeutic Targets
41. Patient-Reported Outcomes in Clinical Trials of CKD-Related Therapies: Report of a Symposium Sponsored by the National Kidney Foundation and the US Food and Drug Administration
    Ronald D. Perrone, Stephen Joel Coons, Kerri L. Cavanaugh, Fred Finkelstein, Klemens B. Meyer · 2013 · American Journal of Kidney Diseases
42. Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease
    Ashraf I. Mikhail, Rajesh Shrivastava, Donald Richardson · 2011 · Nephron Clinical Practice
43. Low Hemoglobin Levels and Hypo‐Responsiveness to Erythropoiesis‐Stimulating Agent Associated With Poor Survival in Incident J apanese Hemodialysis Patients
    Tadao Akizawa, Akira Saitō, Fumitake Gejyo, Masashi Suzuki, Yoshiki Nishizawà, Yasuhiko Tomino, Yoshiharu Tsubakihara, Takashi Akiba, Hideki Hirakata, Yuzo Watanabe et al. · 2014 · Therapeutic Apheresis and Dialysis
44. How important is transfusion avoidance in 2013?
    Iain C. Macdougall, Gregorio T. Obrador · 2013 · Nephrology Dialysis Transplantation
45. The New FDA Labeling for ESA—Implications for Patients and Providers
    Braden Manns, Marcello A. Tonelli · 2012 · Clinical Journal of the American Society of Nephrology
46. The Future of Clinical Trials in Cardiovascular Medicine
    Scott David Solomon, Marc Alan Pfeffer · 2016 · Circulation
47. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach
    Sumeska Thavarajah, Michael Jin Choi · 2019 · American Journal of Kidney Diseases
48. Anemia in patients of diabetic kidney disease
    Shang-Feng Tsai, Der‐Cherng Tarng · 2019 · Journal of the Chinese Medical Association
49. Drug-Induced Hypertension
    Matthew C. Foy, Joban Vaishnav, Christopher John Sperati · 2019 · Endocrinology and Metabolism Clinics of North America
50. A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease
    Verena Petzer, Piotr Tymoszuk, Malte Aßhoff, Joana Azevedo Carvalho, Jonathan Papworth, Cecilia Deantonio, Luke Bayliss, Matthew Wake, Markus Seifert, Natascha Brigo et al. · 2020 · Blood
51. How I treat renal anemia
    Steven N. Fishbane, Daniel W. Coyne · 2020 · Blood
52. Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres
    Miklos Zsolt Molnar, István Mucsi, Iain C. Macdougall, James Ernest Marsh, Magdi M. Yaqoob, John Main, Aisling E. Courtney, D. J. FOGARTY, Ashraf I. Mikhail, Gabriel J. Choukroun et al. · 2010 · Nephron Clinical Practice
53. Blood disorders after kidney transplantation
    Roman Reindl‐Schwaighofer, Rainer W. Oberbauer · 2013 · Transplantation Reviews
54. Peripheral Nerve Regeneration: Opportunities and Challenges
    Rajiv Supra, Devendra K. Agrawal · 2023 · Journal of Spine Research and Surgery
55. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD
    Peter Noel Van Buren, Ruben L. Velez, Nosratola D. Vaziri, Xin J. Zhou · 2011 · International Urology and Nephrology
56. Relationship between chronic kidney disease prevalence and end-stage renal disease risk
    Stein Ivar Hallan, Bjørn Egil Vikse · 2008 · Current Opinion in Nephrology & Hypertension
57. Role of Uremic Toxins in Erythropoiesis-Stimulating Agent Resistance in Chronic Kidney Disease and Dialysis Patients
    Masaomi Nangaku, Imari Mimura, Junna Yamaguchi, Yoshiki Higashijima, Takehiko Wada, Tetsuhiro Tanaka · 2014 · Journal of Renal Nutrition
58. Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling
    Kelsey G. DeFrates, Daniela Franco, Ellen Heber‐Katz, Phillip B. Messersmith · 2021 · Biomaterials
59. G‐Estimation and Artificial Censoring: Problems, Challenges, and Applications
    Marshall M. Joffe, Wei Peter Yang, Harold I. Feldman · 2011 · Biometrics
60. Erythropoietin: physiology and molecular mechanisms
    Robert N. Foley · 2008 · Heart Failure Reviews
61. Editorial Focus: Thrombosis with Erythropoietic Stimulating Agents—Does Iron‐Deficient Erythropoiesis Play a Role?
    Naomi V. Dahl, David H. Henry, Daniel W. Coyne · 2008 · Seminars in Dialysis
62. Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST
    Christian W. Hamm, Jean‐Pierre Bassand, Stefan Agewall, Jeroen Joost Bax, Eric H. Boersma, Héctor Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber et al. · 2012 · Revista Española de Cardiología
63. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
    Jing Li, Volker H. Haase, Chuan‐Ming Hao · 2022 · Kidney Diseases
64. Iron deficiency and supplementation in heart failure
    Samira Lakhal‐Littleton, John G.F. Cleland · 2024 · Nature Reviews Cardiology
65. CONFERENCE REPORT: Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
    Aryeh Shander, Ríchard K. Spence, Michael Auerbach · 2009 · Transfusion
66. Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease
    Matthew R. Weir, Jeffrey Craig Fink · 2014 · Current Opinion in Nephrology & Hypertension
67. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort
    Meredith A. Atkinson, Ji Young Kim, Cindy N. Roy, Bradley A. Warady, Colin Thomas White, Susan L. Furth · 2014 · Pediatric Nephrology
68. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients
    Norio Hanafusa, Takanobu Nomura, Takeshi Hasegawa, Masaomi Nangaku · 2014 · Nephrology Dialysis Transplantation
69. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
    Iain C. Macdougall, Andreas H. Bock, Fernando Carrera, Kai‐Uwe Eckardt, Sandrine Gaillard, David Van Wyck, Bernard Roubert, Timothy Cushway, Simon D. Roger, on Behalf of the FIND-CKD Study Investigators · 2013 · Nephrology Dialysis Transplantation
70. How Can We Improve the Quality of Life of Dialysis Patients?
    Donald G. Mitema, Bernard G. Jaar · 2016 · Seminars in Dialysis
71. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease
    Danilo Fliser · 2010 · Journal of Nephrology
72. Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases
    Verena Petzer, Igor Theurl, Günter Weiß · 2018 · Pharmaceuticals
73. The case for intervention bias in the practice of medicine.
    Andrew Foy, Edward John Filippone · 2013 · Europe PMC (PubMed Central)
74. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?
    Nosratola D. Vaziri · 2008 · Nature Reviews Nephrology
75. Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients – the Hong Kong diabetes registry
    Xilin Yang, Ronald C.W., Wing‐Yee So, Gary T C Ko, Alice P.S. Kong, Christopher Wai Kei Lam, Chun-Shun Ho, Clive Stewart Cockram, Vivian C. W. Wong, Peter C.Y. Tong et al. · 2007 · Cardiovascular Diabetology
76. Adverse Effects on Hemostatic Function of Drugs Used in Hematologic Malignancies
    Anaadriana Zakarija, Hau C. Kwaan · 2007 · Seminars in Thrombosis and Hemostasis
77. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease
    Kirsten L. Johansen, Alexander R. Cobitz, Ajay K. Singh, Iain C. Macdougall, Renato D. Lópes, Gregorio T. Obrador, Csaba Pal Kovesdy, Rubeen Israni, Vivekanand Jha, Tony Okoro et al. · 2023 · Kidney International
78. Erythropoietic Stimulating Agents and Quality of a Patient’s Life
    Alan S. Kliger, Steven N. Fishbane, Fredric O. Finkelstein · 2012 · Clinical Journal of the American Society of Nephrology
79. The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure
    Yossi Chait, Sahir Kalim, Joseph Horowitz, C.V. Hollot, Elizabeth D. Ankers, Michael J. Germain, Ravi Thadhani · 2016 · Hemodialysis International
80. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM‐HD Study
    Ko‐Lin Kuo, Szu‐Chun Hung, Wei‐Cheng Tseng, Ming‐Tsun Tsai, Jia‐Sin Liu, Ming‐Huang Lin, Chih‐Cheng Hsu, Der‐Cherng Tarng, the Taiwan Society of Nephrology Renal Registry Data System, Shuo‐Ming Ou et al. · 2018 · Journal of the American Heart Association
81. Quality of Life in Dialysis Patients: A Retrospective Cohort Study
    Natascha J.H. Broers, Len A. Usvyat, Jeroen Peter Kooman, Frank M. VAN DER SANDE, Eduardo Lacson, Peter Kotanko, Franklin W. Maddux · 2015 · The Nephron journals/Nephron journals
82. Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease
    Csaba Pal Kovesdy, Kamyar Kalantar‐Zadeh · 2009 · Nephrology
83. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions
    Donald S. Silverberg, Dov Wexler, Adrian Iaina, Doron Schwartz · 2008 · Clinical and Experimental Nephrology
84. Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy
    Robert N. Foley, Bryan M. Curtis, Patrick S. Parfrey · 2008 · Clinical Journal of the American Society of Nephrology
85. CERA: third-generation erythropoiesis-stimulating agent
    Joel Michels Topf · 2008 · Expert Opinion on Pharmacotherapy
86. Chapter 5: Referral to specialists and models of care
    2012 · Kidney International Supplements
87. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death
    Areef Ishani, Craig A. Solid, Eric D. Weinhandl, David T. Gilbertson, Robert N. Foley, A.J. Collins · 2007 · Nephrology Dialysis Transplantation
88. Proteinuria as a surrogate end point—more data are needed
    Aliza Thompson · 2012 · Nature Reviews Nephrology
89. An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD
    Fiona M Clement, Scott W Klarenbach, Marcello A. Tonelli, Natasha Wiebe, Brenda R. Hemmelgarn, Braden Manns · 2010 · American Journal of Kidney Diseases
90. Advancements in anemias related to chronic conditions
    Gian Cesare Guidi, Clara Lechi Santonastaso · 2010 · Clinical Chemistry and Laboratory Medicine (CCLM)
91. Iron dosing in kidney disease: inconsistency of evidence and clinical practice
    A.E. Gaweda, Yelena Z. Ginzburg, Yossi Chait, Michael J. Germain, George R. Aronoff, Eliezer A. Rachmilewitz · 2014 · Nephrology Dialysis Transplantation
92. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease
    Yoshiro Naito, Aya Fujii, Hisashi Sawada, Shinichi Hirotani, Toshihiro Iwasaku, Akiyo Eguchi, Mitsumasa Ohyanagi, Takeshi Tsujino, Tohru Masuyama · 2012 · Journal of Hypertension
93. Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
    Simon D. Roger, Martin Tio, Hyeong Cheon Park, Hui Lin Choong, Bak Leong Goh, Timothy Cushway, Vanessa Stevens, Iain C. Macdougall · 2016 · Nephrology
94. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    Wendy L. St. Peter, Lori D Wazny, Eric D. Weinhandl, Katie E. Cardone, Joanna Q. Hudson · 2017 · Drugs
95. HIF Activation Against CVD in CKD: Novel Treatment Opportunities
    Tetsuhiro Tanaka, Kai‐Uwe Eckardt · 2018 · Seminars in Nephrology
96. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    Angelo Karaboyas, Hal Morgenstern, Nancy L. Fleischer, Raymond Camille Vanholder, Nafeesa N Dhalwani, Elke Schäeffner, Douglas Earl Schaubel, Tadao Akizawa, Glen James, Marvin V. Sinsakul et al. · 2020 · Kidney Medicine
97. Measuring health-related quality of life in patients with end-stage renal disease: why and how
    Shunichi Fukuhara, Shin Yamazaki, Yasuaki Hayashino, Joseph Green · 2007 · Nature Reviews Nephrology
98. Causes and consequences of inflammation on anemia management in hemodialysis patients
    Lakhmir S. Chawla, Mahesh Krishnan · 2009 · Hemodialysis International
99. Projecting future drug expenditures—2008
    James M. Hoffman, Nilay D. Shah, Lee C. Vermeulen, Fred Doloresco, Penny Grim, Robert J. Hunkler, Karrie M. Hontz, Glen T. Schumock · 2008 · American Journal of Health-System Pharmacy
100. References
     2012 · Kidney International Supplements